Btk
Bruton tyrosine kinase
Bruton tyrosine kinase (Btk) is a member of the Tec family kinases with a well-characterized role in B-cell antigen receptor (BCR)-signaling and B-cell activation.
Btk plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity. Btk is a kinase expressed exclusively in B cells and myeloid cells and has a well characterized, vital role in B cells highlighted by the human primary immune deficiency disease, X-linked agammaglobulinemia (XLA), which results from mutation in the Btk gene. Btk plays an essential role in the BCR signaling pathway. Antigen binding to the BCR results in B cell receptor oligomerization, Syk and Lyn kinase activation, followed by Btk kinase activation. Once activated, Btk forms a signaling complex with proteins such as BLNK, Lyn, and Syk and phosphorylates phospholipase C (PLC)γ2. This leads to downstream release of intracellular Ca2+ stores and propagation of the BCR signaling pathway through extracellular signal-regulated kinase and NF-κB signaling, ultimately resulting in transcriptional changes to foster B cell survival, proliferation, and/or differentiation.
All Product Categories
-
Btk Related Products (271)
Related Products (271)
-
Recombinant Proteins (19)
-
Antibodies (3)
-
BTK-IN-14
0 ImagesCat. No.: HY-147584CAS No.: 2764674-60-2BTK-IN-14 is a potent inhibitor of BTK. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-14 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022057894A1, compound 1).
-
BTK-IN-20
0 ImagesCat. No.: HY-148832CAS No.: 1581714-50-2
-
BTK-IN-27
0 ImagesCat. No.: HY-156553CAS No.: 1841502-36-0
-
BTK-IN-11
0 ImagesCat. No.: HY-147581CAS No.: 2765852-46-6BTK-IN-11 is a potent inhibitor of BTK. BTK plays an important role in signaling mediated by B cell antigen receptor (BCR) and Fcγreceptor (FcγR) in B cells and myeloid cells, respectively. BTK-IN-11 has the potential for the research of related diseases, especially autoimmune diseases, inflammatory diseases or cancer (extracted from patent WO2022063101A1, compound Z2).
-
JAK3/BTK-IN-3
0 ImagesCat. No.: HY-143718CAS No.: 2674036-98-5JAK3/BTK-IN-3 is a potent inhibitor of JAK3/BTK. BTK and JAK3 are two important targets for autoimmune diseases. Simultaneous inhibition of the BTK/JAK3 signalling pathway exhibits synergistic effects. JAK3/BTK-IN-3 has the potential for the research of JAK3 kinase and/or BTK-related diseases (extracted from patent WO2021147952A1, compound 009)
-
CA/PRAK-IN-1
0 ImagesCat. No.: HY-184792CA/PRAK-IN-1 is a dual inhibitor of carbonic anhydrase (Carbonic Anhydrase) and PRAK, with a Ki of 20.1 nM against hCA IX and 16.4 nM against hCA XII. CA/PRAK-IN-1 exhibits inhibitory activity against YES1 kinase, BTK, and MAP4K3. CA/PRAK-IN-1 induces G0/G1 phase arrest of the cancer cell cycle, inhibits DNA synthesis, disrupts hypoxia-driven survival pathways, promotes cell death, and shows broad-spectrum cytotoxicity against tumor cells. CA/PRAK-IN-1 can be used in research on various cancers including leukemia, colon cancer, melanoma, and renal cancer.
-
GSTO1-IN-2
0 ImagesCat. No.: HY-161876CAS No.: 3020776-77-3GSTO1-IN-2 (Compound B-9) is a dual covalent inhibitor of GSTO1/BTK with IC50 values of 441 nM and 6.2 nM respectively.
-
JAK3/BTK-IN-7
0 ImagesCat. No.: HY-163183CAS No.: 2844387-16-0JAK3/BTK-IN-7 (XL-12) is a JAK3/BTK inhibitor with IC50 values of 2 nM and 14 nM, respectively. JAK3/BTK-IN-7 has anti-inflammatory activity and can be used in the study of rheumatoid arthritis.
-
BTK-IN-18
0 ImagesCat. No.: HY-152201CAS No.: 1374239-71-0
-
BTK-IN-41
0 ImagesCat. No.: HY-171131CAS No.: 2251799-53-6BTK-IN-41 (Compound 47) is the inhibitor for BTK with an IC50 of 5.4 nM. BTK-IN-41 inhibits the diffuse large B cell lymphoma cell TDM-8 with IC50 of 13.8 nM.
-
BTK-IN-47
0 ImagesCat. No.: HY-181996BTK-IN-47 (Compound 9e) is a covalent, selective BTK inhibitor with an IC50 of 5.15 nM against BTK. BTK-IN-47 inhibits the BTK signaling pathway, induces cell cycle arrest, and activates the canonical Caspase-dependent Apoptotic pathway (promoting the cleavage of Caspase-3, Caspase-7 and PARP), without inducing necroptosis, pyroptosis or ferroptosis. BTK-IN-47 exerts dose-dependent antiproliferative activity against hematologic tumor cell lines. BTK-IN-47 exhibits dose-dependent in vivo antitumor activity in a Ramos cell xenograft model in BALB/c nude mice. BTK-IN-47 can be used for the research of hematologic malignancies.
-
GFH647
0 ImagesCat. No.: HY-160219SCAS No.: 2765854-31-5Synonyms: BTK-IN-33GFH647 (BTK-IN-33) is a Btk inhibitor with anticancer effects (WO2023174300A1; compound I).
-
PF-303
0 ImagesCat. No.: HY-164002CAS No.: 1609465-78-2PF-303 is a potent, oral inhibitor of Bruton's tyrosine kinase (BTK) (IC50=0.64 nM). The melamine portion of PF-303 forms a covalent bond with BTK's Cys481, which is reversible and exhibits a high selectivity compared to irreversible covalent BTK inhibitors. PF-303 can be used to model and study the effects of BTK inhibition on the mature immune system, including effects on B-cell subsets, antibody responses, and T-cell-mediated activation.
-
BTK-IN-40
0 ImagesCat. No.: HY-170324CAS No.: 1791400-83-3BTK-IN-40 (compound 375) is a BTK inhibitor.
-
WS-11
0 ImagesCat. No.: HY-169228CAS No.: 2759280-09-4
-
BTK-IN-26
0 ImagesCat. No.: HY-153951SCAS No.: 2762043-61-6
-
BTK-IN-50
0 ImagesCat. No.: HY-184940BTK-IN-50 is a covalent BTK inhibitor with an IC50 of 6 nM. BTK-IN-50 blocks collagen-induced platelet aggregation by inhibiting the GPVI-mediated BTK-PLCγ2-PKC signaling cascade, and attenuates CRP-XL-induced phosphorylation of BTK, PLCγ2 and PKC substrates in platelets. BTK-IN-50 can be used for research related to thrombosis.
